The Psychedelics Newsletter

UK MPs welcome psychedelic research, Big pharma backs psychedelic medicine with acquisition, Phase II psilocybin study for major depressive disorder.

Cybin acquires Small Pharma, UK government issues response on psychedelic research, One-third of those under 50 open to psychedelic medicine.

Investors back psychedelic healthcare with US$285 million investment, The use of psychedelic medicines is at a record high, How consciousness may rely on brain cells acting collectively.

World-first study to explore psilocybin for gambling addiction, How psychedelic medicines impact brain oscillations, Psychedelic medicines in the treatment of alcoholism.

How psychedelics could help those living with alcohol use disorders, Psilocybin therapy for anorexia nervosa, Oregon's lucrative psychedelic industry.

Neuroimaging study measures brain activity under psychedelic medicines, Awakn completes the sale of Awakn clinics in Norway, Navigating the industry shakeout.

Psychedelics should be at forefront of EU mental health efforts, urge PAREA, Psilocybin in the treatment of anorexia nervosa, A drug developer's guide to navigating psychedelic trials.

PSYCH Symposium: shifting perceptions, in conversation with Robin Carhart-Harris, The impact of SSRIs on psilocybin-assisted therapy, Psychedelic solutions for police and society.

PSYCH Symposium: exploring psychedelic medicine, Advancing psychedelic healthcare in Europe, Neuroimaging and psychedelic medicine.

Exploring eating disorders and psychedelics, Awakn Life Sciences completes sale of Awakn clinics, Innovating the delivery of psychedelic-assisted therapy.

FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs, MHRA approves psilocin trial for major depressive disorder, 61% of Americans support legalisation of psychedelic therapy.

Psych Capital acquires Shortwave Pharma, The future of psychedelic medicine in the EU, Psychedelic medicines and pro-social preferences.